Drugs Affecting Blood and Blood Formation — MCQs

Drugs Affecting Blood and Blood Formation Indian Medical PG Practice Questions and MCQs

Question 241: With oral iron therapy, when can a rise in hemoglobin percentage be observed?

A. 1 week
B. 3 weeks (Correct Answer)
C. 4 weeks
D. 6 weeks

Explanation: **Explanation:** The therapeutic response to oral iron therapy in patients with iron deficiency anemia (IDA) follows a predictable physiological timeline. While the bone marrow begins producing new red blood cells quickly, a measurable rise in hemoglobin (Hb) concentration takes time to manifest in the peripheral blood. 1. **Why 3 weeks is correct:** After starting oral iron, the **reticulocyte count** peaks within 7–10 days (the earliest sign of response). However, a significant and clinically observable **rise in hemoglobin** (typically 2 g/dL or more) generally takes about **3 weeks**. Complete normalization of hemoglobin levels usually occurs within 2 months of therapy. 2. **Analysis of Incorrect Options:** * **1 week (Option A):** At this stage, only the reticulocyte count increases. Hemoglobin levels have not yet risen significantly. * **4 weeks (Option B) & 6 weeks (Option D):** While hemoglobin continues to rise during these periods, the *initial* observable rise occurs earlier, at the 3-week mark. These options represent the progression toward normalization rather than the first point of measurable increase. **NEET-PG High-Yield Pearls:** * **Earliest sign of response:** Increase in Reticulocyte count (peaks at 7–10 days). * **Rate of Hb rise:** Approximately 0.1 g/dL per day or 0.5–1.0 g/dL per week. * **Duration of therapy:** Iron should be continued for **3–6 months** *after* hemoglobin normalizes to replenish depleted iron stores (measured by Serum Ferritin). * **Best Absorption:** Oral iron is best absorbed on an empty stomach; Vitamin C (Ascorbic acid) enhances absorption, while antacids, tea, and milk inhibit it.

Question 242: Aspirin is not given to a patient already on heparin because aspirin causes:

A. Platelet dysfunction (Correct Answer)
B. Aspirin inhibits the action of heparin
C. Enhanced hypersensitivity to heparin
D. Heparin therapy cannot be monitored

Explanation: **Explanation:** The correct answer is **A. Platelet dysfunction**. **Mechanism of Action:** Aspirin is an irreversible inhibitor of the enzyme **Cyclooxygenase-1 (COX-1)**. By acetylating the active site of COX-1, it prevents the synthesis of **Thromboxane A2 (TXA2)**, a potent mediator of platelet aggregation and vasoconstriction. Since platelets are anucleated and cannot synthesize new enzymes, this effect lasts for the entire lifespan of the platelet (7–10 days). Heparin acts on the coagulation cascade (primarily by activating Antithrombin III to inhibit Thrombin and Factor Xa). When aspirin is added to heparin therapy, it creates a **dual defect in hemostasis**: heparin impairs the "secondary hemostasis" (clotting factors), while aspirin impairs "primary hemostasis" (platelet plug formation). This synergistic effect significantly increases the risk of spontaneous and life-threatening hemorrhage. **Analysis of Incorrect Options:** * **B. Aspirin inhibits the action of heparin:** Aspirin does not interfere with the pharmacodynamics of heparin; rather, it adds a different layer of anticoagulation risk. * **C. Enhanced hypersensitivity:** There is no known immunological cross-reactivity or enhancement of allergic reactions between these two drugs. * **D. Heparin therapy cannot be monitored:** Heparin is monitored using **aPTT** (activated Partial Thromboplastin Time). Aspirin affects the **Bleeding Time (BT)** but does not interfere with the laboratory measurement of aPTT. **High-Yield Clinical Pearls for NEET-PG:** * **Aspirin + Heparin:** Generally avoided unless the patient is undergoing specific procedures like Percutaneous Coronary Intervention (PCI). * **Antidotes:** Heparin overdose is managed with **Protamine sulfate**; there is no specific antidote for aspirin (management is supportive, including platelet transfusion if necessary). * **Monitoring:** Remember that Aspirin increases **Bleeding Time**, while Heparin increases **aPTT**.

Question 243: Which of the following is true regarding Thromboxane A2?

A. Formed by platelets
B. Formed from PGG2/PGH2
C. Prothrombotic
D. All of the above (Correct Answer)

Explanation: **Explanation:** Thromboxane A2 (TXA2) is a potent eicosanoid derived from arachidonic acid that plays a central role in primary hemostasis [1]. 1. **Site of Synthesis (Option A):** TXA2 is synthesized primarily within **platelets**. Unlike endothelial cells which produce Prostacyclin (PGI2), platelets contain the enzyme **Thromboxane Synthase**, which converts endoperoxides into TXA2. 2. **Biochemical Pathway (Option B):** The synthesis follows the cyclooxygenase (COX) pathway. Arachidonic acid is first converted into the cyclic endoperoxides **PGG2 and PGH2** by the COX-1 enzyme [2]. These intermediates are then specifically converted into TXA2 by thromboxane synthase. 3. **Biological Action (Option C):** TXA2 is highly **prothrombotic**. It acts via G-protein coupled receptors (TP receptors) to cause: * **Platelet Aggregation:** It is a potent stimulator of platelet degranulation and recruitment [1]. * **Vasoconstriction:** It narrows blood vessels to reduce blood flow at the site of injury. Since all three statements are physiologically accurate, **Option D** is the correct answer. **High-Yield NEET-PG Pearls:** * **Aspirin Mechanism:** Low-dose Aspirin irreversibly inhibits **COX-1**, preventing the formation of TXA2 [2]. Since platelets are anucleated and cannot synthesize new enzymes, the effect lasts for the lifetime of the platelet (7–10 days). * **The "Prostacyclin-Thromboxane Balance":** PGI2 (from endothelium) inhibits aggregation and causes vasodilation, while TXA2 (from platelets) promotes aggregation and causes vasoconstriction. * **Half-life:** TXA2 is very unstable and spontaneously hydrolyzes to the inactive metabolite **TXB2** within about 30 seconds [3].

Question 244: Which of the following is not a direct-acting antiplatelet agent?

A. Aspirin
B. Clopidogrel
C. Atorvastatin (Correct Answer)
D. Alteplase

Explanation: **Explanation:** The core of this question lies in distinguishing between drugs that primarily target platelet aggregation and those that affect other parts of the cardiovascular or fibrinolytic systems. **Why Atorvastatin is the correct answer:** **Atorvastatin** is an HMG-CoA reductase inhibitor (Statin) used primarily as a lipid-lowering agent. While statins exhibit "pleiotropic effects"—such as improving endothelial function and stabilizing atherosclerotic plaques—they are **not** classified as direct antiplatelet agents. They do not directly inhibit platelet receptors or enzymes involved in the aggregation cascade. **Analysis of Incorrect Options:** * **Aspirin:** A classic antiplatelet agent. It irreversibly inhibits the **COX-1 enzyme**, preventing the synthesis of Thromboxane A2 (TXA2), a potent platelet aggregator. * **Clopidogrel:** A prodrug that belongs to the P2Y12 receptor blockers. It inhibits the binding of ADP to its platelet receptor, thereby preventing the activation of the GPIIb/IIIa complex. * **Alteplase:** This is a **Thrombolytic (Fibrinolytic)** agent. It is a recombinant tissue plasminogen activator (tPA) that converts plasminogen to plasmin, which then degrades existing fibrin clots. While it affects "blood," it is not an antiplatelet drug. *(Note: In some contexts, Alteplase is considered the "most" incorrect among the choices if the question implies drugs used for long-term prophylaxis, but Atorvastatin remains the definitive non-antiplatelet agent here).* **NEET-PG High-Yield Pearls:** * **P2Y12 Inhibitors:** Remember the difference between irreversible (Clopidogrel, Prasugrel) and reversible (Ticagrelor) inhibitors. * **GPIIb/IIIa Antagonists:** Abciximab, Eptifibatide, and Tirofiban are the "final common pathway" inhibitors of platelet aggregation. * **Dipyridamole:** Acts by inhibiting phosphodiesterase (PDE), increasing cAMP levels in platelets to inhibit aggregation. * **Aspirin Resistance:** Often linked to genetic polymorphisms or concurrent NSAID use (like Ibuprofen) which can block Aspirin’s access to the COX-1 binding site.

Question 245: Red cells are caught as innocent bystanders in the reaction between a drug and antibodies against that drug, leading to hemolysis. Which drug is most commonly responsible for such a reaction?

A. Penicillin (Correct Answer)
B. Sulfonamide
C. Naphthalene
D. Primaquine

Explanation: This question tests your knowledge of **Drug-Induced Immune Hemolytic Anemia (DIIHA)** mechanisms. ### Explanation of the Correct Answer **Penicillin** is the classic example of the **Hapten/Drug-Adsorption Mechanism**. In this process, the drug (penicillin) acts as a hapten and binds firmly to the surface proteins of the Red Blood Cell (RBC). The body then produces high-titer IgG antibodies specifically against the drug-protein complex. The RBCs are described as **"innocent bystanders"** because the immune system is not targeting the RBC antigens themselves, but rather the drug attached to them. When the antibody binds to the drug on the cell surface, the RBC is cleared by splenic macrophages, leading to extravascular hemolysis. This typically occurs with high-dose intravenous penicillin. ### Analysis of Incorrect Options * **B. Sulfonamides:** While sulfonamides can cause hemolysis, they are more frequently associated with the **"Immune Complex" (Bystander) mechanism** (where drug-antibody complexes adsorb non-specifically to RBCs) or oxidative stress in G6PD deficiency. However, Penicillin remains the most common textbook example for the hapten-mediated "innocent bystander" description. * **C. Naphthalene & D. Primaquine:** These drugs cause **Oxidative Hemolysis**, not immune-mediated hemolysis. They induce hemolysis specifically in individuals with **G6PD deficiency** by causing the denaturation of hemoglobin (forming Heinz bodies). ### High-Yield Clinical Pearls for NEET-PG * **Direct Coombs Test:** Usually **positive** for IgG in penicillin-induced hemolysis. * **Three Mechanisms of DIIHA:** 1. **Hapten Type:** Penicillin, Cephalosporins. 2. **Immune Complex Type:** Quinidine, Sulfonamides (Classic "Innocent Bystander" where complement is often activated). 3. **Autoimmune Type:** **Methyldopa** (induces true autoantibodies against Rh antigens; Coombs test remains positive even after stopping the drug). * **Key Distinction:** In the Hapten type (Penicillin), the antibody reacts only with drug-coated cells; in the Autoimmune type (Methyldopa), the antibody reacts with normal RBCs even in the absence of the drug.

Question 246: Heparin is a commonly used anticoagulant in cardiac surgery. All of the following statements about heparin are true EXCEPT:

A. It is the weakest acid found in living beings. (Correct Answer)
B. Most commercial preparations of heparin are derived from pig intestine.
C. It acts by antithrombin activation.
D. It can produce thrombocytopenia.

Explanation: ### Explanation **1. Why Option A is the Correct Answer (The False Statement):** Heparin is actually the **strongest organic acid** found in the human body. It is a highly sulfated glycosaminoglycan with a high density of negative charges. This strong electronegativity is fundamental to its function, as it allows heparin to bind to various proteins, including antithrombin III and coagulation factors. **2. Analysis of Incorrect Options (True Statements):** * **Option B:** Commercial heparin is primarily sourced from **porcine (pig) intestinal mucosa** or bovine (cow) lung. Porcine heparin is more commonly used today. * **Option C:** Heparin acts as an indirect anticoagulant. It binds to **Antithrombin III (AT-III)**, inducing a conformational change that accelerates the inactivation of thrombin (Factor IIa) and Factor Xa by nearly 1,000-fold. * **Option D:** Heparin-Induced Thrombocytopenia (HIT) is a significant adverse effect. **Type II HIT** is an immune-mediated reaction where antibodies form against the Heparin-Platelet Factor 4 (PF4) complex, leading to platelet consumption and a paradoxical prothrombotic state. **3. Clinical Pearls for NEET-PG:** * **Monitoring:** Unfractionated Heparin (UFH) is monitored using **aPTT** (Target: 1.5–2.5 times the control). * **Antidote:** **Protamine sulfate** (a basic protein) neutralizes heparin via a chemical antagonism (acid-base reaction). * **Safety in Pregnancy:** Heparin is the **anticoagulant of choice in pregnancy** because its high molecular weight prevents it from crossing the placenta (unlike Warfarin, which is teratogenic). * **LMWH vs. UFH:** Low Molecular Weight Heparin (e.g., Enoxaparin) mainly inhibits Factor Xa and does not require routine aPTT monitoring.

Question 247: Which among the following is a parenteral iron formulation?

A. Iron hydroxy polymaltose
B. Ferrous fumarate
C. Ferric ammonium citrate
D. Iron sorbitol citric acid complex (Correct Answer)

Explanation: ### Explanation **Correct Option: D (Iron sorbitol citric acid complex)** Iron sorbitol citric acid complex is a **parenteral (injectable)** iron preparation designed for intramuscular (IM) administration. Parenteral iron is indicated when oral iron is not tolerated, in cases of severe malabsorption (e.g., Celiac disease, IBD), or when rapid replenishment of iron stores is required (e.g., advanced pregnancy or chronic kidney disease). Unlike oral iron, which is absorbed via the divalent metal transporter 1 (DMT1) in the duodenum, parenteral formulations bypass the GI tract and are processed by the reticuloendothelial system. **Analysis of Incorrect Options:** * **A. Iron hydroxy polymaltose:** This is a common **oral** iron formulation. It is a non-ionic complex that is generally better tolerated than ferrous salts, causing fewer gastrointestinal side effects. * **B. Ferrous fumarate:** This is a standard **oral** ferrous salt. It contains approximately 33% elemental iron and is widely used for treating iron deficiency anemia due to its high bioavailability and low cost. * **C. Ferric ammonium citrate:** This is an **oral** liquid iron preparation. While it contains ferric iron ($Fe^{3+}$), it must be reduced to the ferrous state ($Fe^{2+}$) in the stomach for absorption. **High-Yield Clinical Pearls for NEET-PG:** * **Parenteral Formulations:** Other common parenteral agents include **Iron Dextran** (highest risk of anaphylaxis), **Iron Sucrose** (commonly used in hemodialysis), and **Ferric Carboxymaltose** (allows for high-dose infusion). * **Adverse Effects:** The most specific side effect of IM iron sorbitol is a **metallic taste** and local pain/staining at the injection site (minimized by the **Z-track technique**). * **Contraindication:** Parenteral iron should never be given concurrently with oral iron, as it can lead to "iron overload" and toxicity due to the saturation of transferrin.

Question 248: Which iron preparation can be administered intravenously?

A. Ferrous sulphate
B. Iron dextran (Correct Answer)
C. Iron sorbitol citric acid complex
D. Colloidal ferric hydroxide

Explanation: **Explanation:** The correct answer is **Iron dextran**. **1. Why Iron Dextran is Correct:** Iron dextran is a high-molecular-weight complex of ferric hydroxide and dextran. It is the classic preparation used for **parenteral iron therapy** and can be administered via both **Intramuscular (IM)** and **Intravenous (IV)** routes. When given IV, it is typically administered as a "Total Dose Infusion" (TDI). It is indicated when oral iron is not tolerated, in cases of severe malabsorption, or when rapid replenishment of iron stores is required (e.g., chronic kidney disease). **2. Analysis of Incorrect Options:** * **Ferrous sulphate (Option A):** This is the standard **oral** iron preparation. It is never given parenterally because free iron ions are highly toxic and can cause systemic oxidative damage. * **Iron sorbitol citric acid complex (Option C):** This preparation has a lower molecular weight and is rapidly absorbed into the circulation. Due to its pharmacokinetics, it is administered **strictly via the Intramuscular (IM) route**; IV administration is contraindicated as it can cause sudden, dangerously high levels of free iron in the plasma. * **Colloidal ferric hydroxide (Option D):** While ferric hydroxide is a component of many complexes, it is not used in its simple colloidal form for IV administration due to stability and toxicity issues. **3. NEET-PG High-Yield Clinical Pearls:** * **Anaphylaxis:** Iron dextran carries a risk of severe anaphylactic reactions. A **test dose** is mandatory before starting the full infusion. * **Newer IV Agents:** Modern practice often prefers **Iron Sucrose** or **Ferric Carboxymaltose** over Iron dextran, as they have a lower risk of anaphylaxis and do not always require a test dose. * **IM Technique:** If giving iron (like Iron sorbitol) intramuscularly, the **Z-track technique** must be used to prevent skin staining.

Question 249: Microcytic hypochromic anemia due to inadequate nutrition is best treated with:

A. Oral ferric chloride
B. Oral ferrous sulfate (Correct Answer)
C. Oral vitamin B12
D. Intramuscular vitamin B12

Explanation: **Explanation:** **1. Why Oral Ferrous Sulfate is Correct:** Microcytic hypochromic anemia is the hallmark of **Iron Deficiency Anemia (IDA)**. In cases of inadequate nutrition, the primary goal is to replenish iron stores. **Oral ferrous salts** (divalent iron) are the treatment of choice because iron is absorbed from the gastrointestinal tract in the ferrous ($Fe^{2+}$) state. Ferrous sulfate is the most commonly prescribed preparation due to its high elemental iron content (approx. 20%), cost-effectiveness, and proven efficacy in raising hemoglobin levels. **2. Why the Other Options are Incorrect:** * **Oral Ferric Chloride:** Ferric iron ($Fe^{3+}$) must be converted to the ferrous state by gastric acid and ferrireductase before absorption. Ferric salts are generally less soluble at alkaline pH and have significantly lower bioavailability compared to ferrous salts. * **Vitamin B12 (Oral/IM):** Vitamin B12 deficiency causes **Megaloblastic (Macrocytic) Anemia**, characterized by an increased Mean Corpuscular Volume (MCV). It would not be effective for microcytic (low MCV) anemia. **3. NEET-PG High-Yield Pearls:** * **Absorption:** Iron is primarily absorbed in the **duodenum and upper jejunum**. Absorption is enhanced by Vitamin C (ascorbic acid) and inhibited by phosphates, phytates (cereals), and tetracyclines. * **Response to Therapy:** The earliest indicator of response to iron therapy is a **rise in reticulocyte count**, peaking at 5–10 days. Hemoglobin typically rises by 2 g/dL every 3 weeks. * **Side Effects:** The most common side effects of oral iron are GI-related (nausea, epigastric pain, constipation, and black stools). * **Parenteral Iron:** Reserved for patients with malabsorption, intolerance to oral iron, or chronic kidney disease (e.g., Iron Sucrose or Ferric Carboxymaltose).

Question 250: Apixaban is a new drug that acts by:

A. Inhibiting TNF alpha
B. Inhibiting coagulation factor Xa (Correct Answer)
C. Inhibiting platelet aggregation
D. Activating plasminogen

Explanation: **Explanation:** **Apixaban** is a member of the **Direct Oral Anticoagulants (DOACs)** class. Its mechanism of action involves the direct, highly selective, and reversible inhibition of **Factor Xa** (both free and clot-bound). Factor Xa is the "nexus" of the coagulation cascade where the intrinsic and extrinsic pathways converge to form the common pathway. By inhibiting Factor Xa, apixaban prevents the conversion of prothrombin to thrombin, thereby stopping fibrin clot formation. **Analysis of Incorrect Options:** * **Option A (TNF-alpha inhibitors):** These include drugs like Etanercept, Infliximab, and Adalimumab, which are used as DMARDs in rheumatoid arthritis and IBD, not as anticoagulants. * **Option C (Platelet aggregation inhibitors):** This describes antiplatelet drugs like Aspirin (COX inhibitor) or Clopidogrel (P2Y12 inhibitor), which act on primary hemostasis rather than the coagulation cascade. * **Option D (Plasminogen activators):** This describes thrombolytic/fibrinolytic agents like Alteplase, Reteplase, or Streptokinase, which dissolve existing clots rather than preventing their formation. **High-Yield Clinical Pearls for NEET-PG:** * **The "Xa" Rule:** Drugs with "**xa**" in their name (Api**xa**ban, Rivaro**xa**ban, Edo**xa**ban) are direct Factor **Xa** inhibitors. * **Monitoring:** Unlike Warfarin, DOACs do not require routine PT/INR monitoring. * **Antidote:** The specific reversal agent for Apixaban and Rivaroxaban is **Andexanet alfa**. * **Clinical Use:** Preferred over Warfarin for non-valvular atrial fibrillation and the treatment/prophylaxis of DVT and pulmonary embolism due to a lower risk of intracranial hemorrhage.

Practice by Chapter

Hematopoietic Growth Factors

Practice Questions

Iron Preparations and Management of Iron Deficiency

Practice Questions

Vitamin B12 and Folic Acid

Practice Questions

Anticoagulants: Heparins and Direct Inhibitors

Practice Questions

Oral Anticoagulants

Practice Questions

Antiplatelet Drugs

Practice Questions

Thrombolytic Agents

Practice Questions

Hemostatic Drugs

Practice Questions

Plasma Expanders

Practice Questions

Blood Transfusion and Alternatives

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free